Form 4: Relay Therapeutics Executive Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, sold 1,621 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

  • Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 1,621 shares of common stock on October 28, 2024.
  • The sale was executed at a price of $6.06 per share.
  • The transaction was to cover income tax withholding obligations related to the vesting of 5,506 restricted stock units (RSUs) on October 27, 2024.
  • Rahmer had no discretion over the sale, which was conducted according to Relay Therapeutics' policies.
  • Following the transaction, Rahmer beneficially owns 390,063 shares of Relay Therapeutics, including 371,439 shares underlying RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to tax obligations, not indicative of a significant positive or negative outlook for the company.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction. It's common for executives to sell shares to cover tax obligations when RSUs vest. The impact on the stock is usually minimal unless the transaction is unusually large.

Key Dates

DateDescription
10/27/2024Vesting of 5,506 restricted stock units (RSUs)
10/28/2024Sale of 1,621 shares of common stock
10/30/2024Date of signature on the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.